Skip to main content

Table 5 Post-procedural follo-up

From: Long-term follow-up of therapeutic efficacy of everolimus-eluting bioresorbable vascular scaffold in comparison to everolimus-eluting stent in treatment of chronic total occlusion guided by intracoronary imaging

  EES group BVS group χ2 test p value Sig.
No. = 40 No. = 20
Mortality
 1 month Negative 40 (100%) 20 (100%)
Positive 0 (0%) 0 (0%)
 6 months Negative 40 (100%) 20 (100%)
Positive 0 (0%) 0 (0%)
 1 year Negative 40 (100%) 20 (100%)
Positive 0 (0%) 0 (0%)
Non-fatal MI
 1 month Negative 40 (100%) 20 (100%)
Positive 0 (0%) 0 (0%)
 6 months Negative 40 (100%) 20 (100%)
Positive 0 (0%) 0 (0%)
 1 year Negative 39 (97.5%) 20 (100%) 0.508 0.476 NS
Positive 1 (2.5%) 0 (0%)
UA requiring hospitalization
 1 month Negative 40 (100%) 20 (100%)
Positive 0 (0%) 0 (0%)
 6 months Negative 25 (62.5%) 14 (70%) 0.330 0.566 NS
Positive 15 (37.5%) 6 (30.0%)
 1 year Negative 39 (97.5%) 20 (100%) 0.508 0.476 NS
Positive 1 (2.5%) 0 (0%)
Multi-slice CT (MSCT)
 6 months Patent 36 (90%) 18 (90%) 0.000 1.000 NS
Occluded 4 (10%) 2 (10%)
 1 year Patent 36 (90%) 18 (90%) 0.000 1.000 NS
Occluded 4 (10%) 2 (10%)
  1. MI myocardial infarction, UA unstable angina